Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-06
1999-01-12
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3140
Patent
active
058590439
ABSTRACT:
Kappa-opioid agonists prevent the impairment of renal function otherwise caused by the combination of gaseous anesthesia and surgery or severe trauma. Not only do these agents preserve renal function and maintain urine output, they also maintain plasma electrolyte concentration and osmolality by reducing renal loss of sodium and potassium when compared to other diuretic agents. The preservation of urine flow as well as the ability to retain body sodium, potassium, calcium, and osmolality during surgery or severe trauma under gaseous anesthesia are novel and unique properties associated only with kappa opioid agonists. To date, no other clinically-used diuretic agent has been shown to provide constant urine flow, or to retain electrolytes during anesthesia and surgery. The kappa opioid agonists may be used in surgical patients with normal cardiovascular function, but are particularly useful in patients with compromised cardiovascular and/or renal function.
REFERENCES:
patent: 4663343 (1987-05-01), Horwell et al.
patent: 4888355 (1989-12-01), Clemence et al.
patent: 4891379 (1990-01-01), Zimmerman et al.
patent: 4906655 (1990-03-01), Horwell et al.
patent: 4965278 (1990-10-01), Horwell et al.
patent: 4988727 (1991-01-01), Clemence et al.
patent: 4992450 (1991-02-01), Zimmerman et al.
patent: 5019588 (1991-05-01), Horwell et al.
patent: 5063242 (1991-11-01), Horwell et al.
patent: 5064834 (1991-11-01), Zimmerman et al.
patent: 5068244 (1991-11-01), Moura et al.
patent: 5116842 (1992-05-01), Naylor et al.
patent: 5130329 (1992-07-01), Moura et al.
patent: 5317028 (1994-05-01), McKnight et al.
patent: 5319087 (1994-06-01), Zimmerman et al.
patent: 5369105 (1994-11-01), McKnight et al.
patent: 5384113 (1995-01-01), Deutsch et al.
patent: 5422356 (1995-06-01), Zimmerman et al.
Salas et al., J. Pharmac. Exp. Ther. 262(3), 979-86 (1992).
Salas et al., J. of Pharmacology and Experimental Therapeutics, 250:992-999, 1989.
Y. Hamaya et al., "Diuretic Effect of Clonidine during Isoflurane, Nitrous Oxide, and Oxygen Anesthesia," Anesthesiology, vol. 81, pp. 811-819 (1994).
G. Slizgi et al., "Effects of the Highly Selective Kappa Opioid, U-50,488, on Renal Function in the Anesthetized Dog," J. Pharmacol. Exp. Ther., vol. 230, pp. 641-645 (1984).
G. Peters et al., "Diuretic Actions in Man of a Selective Kappa Opioid Agonist: U-62,066E," J. Pharmacol. Exp. Ther., vol. 240, pp. 128-131 (1987).
G. Rimoy et al., "The Cardiovascular and Central Nervous System Effects in the Human of U-62,066E," Eur. J. Clin. Pharmacol, vol. 46, pp. 203-207 (1994).
D. Brooks et al., "Opiate Receptors in the Blood-Brain Barrier Mediate Kappa Agonist-Induced Water Diuresis," J. Pharmacol. Exp. Ther., vol. 266, pp. 164-171 (1993).
D.R. Bevan et al., "Renal Function During and After Anaesthesia and Surgery: Significance for Water and Electrolyte Management," Brit. J. Anaesth., vol. 45, pp. 968-975 (1973).
Kapusta, "Opioid Mechanisms Controlling Renal Function," Clin. Exp. Pharmacol. Physiol. vol. 22, pp. 891-902 (1995).
N. Ashton, ".kappa.-Opioid-Receptor Agonists Modulate the Renal Excretion of Water and Electrolytes in Anaesthetized Rats," Br. J. Pharmacol., vol. 99, pp. 181-185 (1990).
P. Reece et al., "Diuretic Effects, Pharmacokinetics, and Safety of a New Centrally Acting Kappa-Opioid Agonist (CI-977) in Humans," J. Clin. Pharmacol., vol. 34, pp. 1126-1132 (1994).
D. Kapusta et al., "Role of Renal Nerves in Excretory Responses to Administration of Kappa Agonists in Conscious Spontaneously Hypertensive Rats," J. Pharmacol. Exp. Ther., vol. 251, pp. 230-237 (1989).
D. Kapusta et al., "Central Kappa Opioid Receptor-Evoked Changes in Renal Function in Conscious Rats: Participation of the Renal Nerves," J. Pharmacol. Exp. Ther., vol. 267, pp. 197-204 (1993).
D. Kapusta et al., "Central Kappa Opioids Blunt the Renal Excretory Responses to Volume Expansion by a Renal Nerve-Dependent Mechanism," J. Pharmacol. Exp. Ther., vol. 273, pp. 199-205 (1995).
G. Rimoy et al., "Mechanism of diuretic action of spiradoline (U-62,066E)--a Kappa Opioid Receptor Agonist in the Human," Br. J. Clin. Pharmac., vol. 32, pp. 611-615 (1991).
Board of Supervisors of Louisiana State University and Agricultu
Runnels John H.
Spivack Phyllis G.
LandOfFree
Method for maintaining kidney function during surgery or severe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for maintaining kidney function during surgery or severe , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for maintaining kidney function during surgery or severe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1516423